Recursion Pharmaceuticals (RXRX) Stock Price
Recursion Pharmaceuticals Price
Revenue has compounded at 87.6% per year over the past 6 years to 74.68 M USD. Recursion Pharmaceuticals's net margin stands at -863.4%, up from -1,780.7% several years earlier. Analysts set a median price target of 5.30 USD, implying 40.1% above the current price. Of 13 analysts, 8 rate the stock a buy — an overall Buy consensus.
Recursion Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Recursion Pharmaceuticals business model & stock analysis
Frequently asked questions about Recursion Pharmaceuticals
Analysts currently set an average price target of 5.30 USD for the Recursion Pharmaceuticals stock (median: 5.30 USD), implying +40.1 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Recursion Pharmaceuticals stock: 8 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Recursion Pharmaceuticals to generate revenue of 44.33 M USD and earnings per share of -0.89 USD.
Converted at the current exchange rate, the Recursion Pharmaceuticals share trades at 3.39 EUR (3.78 USD).
The Recursion Pharmaceuticals share (RXRX) is listed on 1 stock exchanges, including: NASDAQ (RXRX).
The expected revenue of Recursion Pharmaceuticals is 44.33 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Recursion Pharmaceuticals is -467.79 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Recursion Pharmaceuticals is currently -4.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Recursion Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Recursion Pharmaceuticals is currently 44.95. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Recursion Pharmaceuticals stock.
The Eulerpool Quality Score for Recursion Pharmaceuticals is 3/10.
The ISIN of Recursion Pharmaceuticals is US75629V1044. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Recursion Pharmaceuticals is RXRX. The ticker symbol is used to trade Recursion Pharmaceuticals shares on the stock exchange.
Recursion Pharmaceuticals stock
Recursion Pharmaceuticals Peer Group
Recursion Pharmaceuticals Ticker
Recursion Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Recursion Pharmaceuticals
Our stock analysis for Recursion Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Recursion Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.